Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts
about
Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translationGRK2 in the heart: a GPCR kinase and beyondCardiovascular gene therapy for myocardial infarctionGene therapy targets in heart failure: the path to translationParoxetine Is a Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial ContractilityAdeno-associated virus-mediated gene therapy in cardiovascular diseaseG protein-coupled receptor kinase 2, with β-arrestin 2, impairs insulin-induced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aortaThe role of G protein coupled receptor kinases in neurocardiovascular pathophysiologyG protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure.The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition.Small molecule disruption of G beta gamma signaling inhibits the progression of heart failureLevel of G protein-coupled receptor kinase-2 determines myocardial ischemia/reperfusion injury via pro- and anti-apoptotic mechanisms.A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension.G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia.G protein coupled receptor kinases as therapeutic targets in cardiovascular disease.G protein-coupled receptor kinases: more than just kinases and not only for GPCRsGene delivery approaches to heart failure treatment.Genetic maneuvers to ameliorate ventricular function in heart failure: therapeutic potential and future implications.Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy.Gene transfer for congestive heart failure: update 2013.Gene therapy in heart failure.G protein βγ subunits: central mediators of G protein-coupled receptor signaling.G protein betagamma subunits as targets for small molecule therapeutic development.Gene therapy to treat cardiovascular disease.Pathological ventricular remodeling: therapies: part 2 of 2.GRK2 as a novel gene therapy target in heart failure.Taking the heart failure battle inside the cell: small molecule targeting of Gβγ subunitsGene therapy for ischemic heart disease.G protein-coupled receptor kinases in normal and failing myocardium.A role for GRK2 in myocardial ischemic injury: indicators of a potential future therapy and diagnostic.Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function.Genetic prediction of heart failure incidence, prognosis and beta-blocker response.Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium.Evolving targeted therapies for right ventricular failure.A Review of the Molecular Mechanisms Underlying the Development and Progression of Cardiac Remodeling.Targeting GPCR-Gβγ-GRK2 signaling as a novel strategy for treating cardiorenal pathologies.Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases.Simultaneous adrenal and cardiac g-protein-coupled receptor-gβγ inhibition halts heart failure progression.Recent findings into the potential of gene therapy to reverse heart failure.
P2860
Q26799437-9603ABDC-E1BD-4F80-954B-E021CC0ED273Q26851548-A4B94BC5-AD24-4089-B824-2F7265EEFC1DQ27014770-151554E5-D3F3-4671-9750-FB28F4A19977Q27022444-75512F24-E83C-46B3-85C3-05B2943470A3Q27671474-2CCCF927-B43B-4413-9A38-20215282E8EAQ28081681-4304EED6-D5BB-446A-8D8D-50028536218FQ28728953-399E0346-8E72-4E0F-8B49-F2639A0559B3Q30459130-D8002D77-4275-4799-9743-EDF2D3B2867FQ30487539-16DF0165-5ED8-4152-850F-B02714665173Q30577637-B735C811-7B7B-4DA1-95C1-E8A923422477Q34077136-1E0521B6-26D4-4B00-85EF-8E450F343405Q34253155-321D12D9-FD5F-4E16-B00D-806E9909307CQ34448395-3BD7E3DC-61E9-4C07-9F0C-23FA8BD0DA71Q35041039-E5A7B920-DBA3-4661-B0A5-6F0A1FDAB853Q35135090-DAE715D5-6CF1-4702-B3B8-5E1E794112AAQ35621624-7AAA0AE3-04E1-446E-8045-0E66B15E9A03Q35873759-006A0B2F-AECA-4B35-925B-787D58B7406FQ36050486-F914BE9F-E3DC-480B-9F0F-0BFB63A07B94Q36480080-56823F7B-73CE-4547-8214-80D21A21A939Q36698991-C4933397-69EB-4CA2-AA19-5CC761C543C3Q36944623-8677036C-0DAF-403C-911D-54C0E39E13FDQ37167274-E448F0BA-AB7B-4484-97FD-1F1CA8C567A7Q37184794-CA28E47E-2D70-4F11-B9FA-C9DDB28B7439Q37310450-67598475-1088-4D49-9A46-3F3AC566786BQ37312758-2E457DD2-3912-4C24-A25A-EDAA5827551BQ37783642-C0CF5681-C7F0-4F47-A2F7-BF554C0EB113Q37831634-166DCC1B-730F-4B65-A030-84D2E9A0148EQ37857290-A4EA51FB-19CF-4F6B-95F5-397488EA7340Q37881660-EA4C75F7-8613-4512-980E-9C3A9839180CQ37907329-3AC07AF4-3ABE-426E-A7B6-3A249A83FA05Q37984182-DC12A814-0971-49E7-B33E-B6815AE77EEFQ38025012-84C54087-A8B3-4C54-8ED2-B17997715D4BQ38099580-FFA34BA9-9F93-412C-8361-70033F2726F8Q38132253-9D8D0372-B93E-494C-A779-7F63C377840FQ38559308-EF8ABA49-5AB8-4A0A-8747-5485481886B9Q38656290-BB0A8703-2DFD-4E5D-86A9-4BA8C8310BDFQ39107039-78C4A71F-94E2-495B-8A52-60B9AD5474F9Q39356341-EA87728A-6C72-4737-A793-FCD1573B9625Q41974755-242DA60E-97DA-470A-A181-01FC8DBC36F6Q45873132-F8F73B76-7FD0-491C-97C9-E5AEA2D5AEE3
P2860
Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@ast
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en-gb
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@nl
type
label
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@ast
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en-gb
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@nl
prefLabel
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@ast
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en-gb
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@nl
P2093
P1433
P1476
Targeted beta-adrenergic recep ...... ansfer in failing human hearts
@en
P2093
Andre Jakoi
Carmelo A Milano
Edward Rampersaud
Jacob Schroder
Jason Petrofski
Jonathan A Hata
Matthew L Williams
Walter J Koch
P304
P356
10.1161/01.CIR.0000125521.40985.28
P407
P577
2004-04-06T00:00:00Z